Precigen, Inc. (NASDAQ:PGEN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Precigen, Inc. (NASDAQ:PGEN) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $10.00.

PGEN has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $14.00 price target on shares of Precigen in a research report on Tuesday, June 4th. Stifel Nicolaus raised their price target on shares of Precigen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 3rd. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Precigen in a research report on Monday, June 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Precigen in a research report on Wednesday, May 15th. Finally, StockNews.com raised shares of Precigen to a “sell” rating in a research report on Tuesday, May 21st.

Institutional Investors Weigh In On Precigen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fortis Group Advisors LLC acquired a new stake in Precigen during the 1st quarter worth $28,000. Fisher Asset Management LLC acquired a new stake in Precigen during the 4th quarter worth $29,000. EntryPoint Capital LLC acquired a new stake in Precigen during the 1st quarter worth $31,000. China Universal Asset Management Co. Ltd. raised its stake in Precigen by 338.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,788 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 22,227 shares in the last quarter. Finally, Diversified Trust Co acquired a new stake in Precigen during the 4th quarter worth $39,000. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Stock Performance

NASDAQ:PGEN opened at $1.54 on Thursday. The stock has a market capitalization of $388.73 million, a P/E ratio of -3.95 and a beta of 1.73. The company has a 50 day moving average price of $1.49 and a 200 day moving average price of $1.44. Precigen has a fifty-two week low of $0.84 and a fifty-two week high of $1.88.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative net margin of 1,781.72% and a negative return on equity of 65.36%. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same period in the prior year, the business earned ($0.10) EPS. Research analysts forecast that Precigen will post -0.36 earnings per share for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.